Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study

  • Heat Biologics Inc HTBX has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Co's BMY Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC) patients.
  • The data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.
  • Median progression-free survival (PFS) in cohort A (n=47) was 1.8 months, and median overall survival (OS) was 24.6 months.
  • Significantly longer PFS and OS in injection site reaction+ patients were observed and longer OS in PD-L1+ patients.
  • In cohort B (n=68), median PFS was 2.8 months, and median OS was 11.9 months.
  • A trend toward extended OS in blood tumor mutational burden with less than ten mutations was seen.
  • Treatment-emergent adverse reactions were reported in 21 (44.7%) patients in cohort A and 18 (26.5%) patients in cohort B.
  • Few HS-110–related adverse reactions led to discontinuation of treatment (cohort A, 5 (10.6%); cohort B, 3 (4.4%), and no serious adverse events were considered related to HS-110.
  • Price Action: HTBX shares are up 4.5% at $6.50 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefslung cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!